癌免疫療法の世界市場見通し:ワクチン、免疫調節物質、モノクローナル抗体、細胞治療、チェックポイント阻害剤

【英語タイトル】Cancer Immunotherapy - Global Market Outlook (2016-2022)

Stratistics MRCが出版した調査資料(SMRC611044)・商品コード:SMRC611044
・発行会社(調査会社):Stratistics MRC
・発行日:2016年10月
・ページ数:157
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥444,050見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥561,750見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥802,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、癌免疫療法の世界市場について調査・分析し、癌免疫療法の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
・エグゼクティブサマリー
・序文
・癌免疫療法の世界市場:市場動向分析
・癌免疫療法の世界市場:競争要因分析
・癌免疫療法の世界市場:セグメント別分析/市場規模
・癌免疫療法の世界市場:地域別分析/市場規模
・癌免疫療法の北米市場規模
・癌免疫療法の欧州市場規模
・癌免疫療法のアジア市場規模
・癌免疫療法の世界市場:主な市場開拓
・関連企業分析
【レポートの概要】

According to Stratistics MRC, the Global Cancer Immunotherapy market is estimated at $54.35 billion in 2015 and is expected to reach $147.25 billion by 2022 growing at a CAGR of 15.3% from 2015 to 2022. Rapid increase in cases of cancer across the globe, smoking and excessive consumption of alcohol which causes cancer are some of the factors fueling the market growth. High cost for the treatment is hampering the market growth. On the other hand rise in clinical trials against different cancers in immunotherapy is the opportunity for the market growth.

Monoclonal Antibodies accounted for the largest share in product type segment and expected to be fastest growing during forecast period. North America captured largest share owing to high mortality rate among cancer patients and government initiative programs to create awareness among the people. Asia Pacific region is expected to be fastest growing during forecast period.

Some of the key players in the market include GlaxoSmithKline, Eli Lilly and Company, F. Hoffmann-LA Roche Ltd, Amgen Inc., Ablynx NV, Bristol-Myers Squibb, Janssen Global Services, LLC (Johnson and Johnson), Astrazeneca, Biovest International Inc, Bayer AG, Oxford BioTherapeutics Ltd., Pfizer, Genentech Inc, Merck, Bellicum Pharmaceuticals Inc and Novartis

Applications Covered:
• Multiple Myeloma
• Prostate Cancer
• Head & Neck Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Breast Cancer
• Other Cancer Types

Product Types Covered:
• Vaccines
o Therapeutic Vaccines
o Prophylactic Vaccines
• Immunomodulators
o Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF)
o Oncolytic Virus
 Immunity as an Ally
 Immunotherapy
 Approved Products & Clinical Trails
 Immunity as an Obstacle
o Interferons (IFN)
o Interleukins (IL)
• Monoclonal Antibodies
o Bispecific Monoclonal Antibodies
o Naked Monoclonal Antibodies
o Conjugated Monoclonal Antibodies
• Cell Therapies
o Dendritic Cells
o Chimeric Antigen Receptor (CAR) T Cell Therapy
• Check Point Inhibitors
o Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
o Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)

End Users Covered:
• Clinics
• Hospital
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Appication Analysis
3.7 End User Analysis
3.8 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Cancer Immunotherapy Market, By Application
5.1 Introduction
5.2 Multiple Myeloma
5.3 Prostate Cancer
5.4 Head & Neck Cancer
5.5 Lung Cancer
5.6 Colorectal Cancer
5.7 Melanoma
5.8 Breast Cancer
5.9 Other Cancer Types

6 Global Cancer Immunotherapy Market, By Product Type
6.1 Introduction
6.2 Vaccines
6.2.1 Therapeutic Vaccines
6.2.2 Prophylactic Vaccines
6.3 Immunomodulators
6.3.1 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF)
6.3.2 Oncolytic Virus
6.3.2.1 Immunity as an Ally
6.3.2.2 Immunotherapy
6.3.2.3 Approved Products & Clinical Trails
6.3.2.4 Immunity as an Obstacle
6.3.3 Interferons (IFN)
6.3.4 Interleukins (IL)
6.4 Monoclonal Antibodies
6.4.1 Bispecific Monoclonal Antibodies
6.4.2 Naked Monoclonal Antibodies
6.4.3 Conjugated Monoclonal Antibodies
6.5 Cell Therapies
6.5.1 Dendritic Cells
6.5.2 Chimeric Antigen Receptor (CAR) T Cell Therapy
6.6 Check Point Inhibitors
6.6.1 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
6.6.2 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)

7 Global Cancer Immunotherapy Market, By End User
7.1 Introduction
7.2 Clinics
7.3 Hospital
7.4 Other End Users

8 Global Cancer Immunotherapy Market, By Geography
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 Italy
8.2.4 UK
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Australia
8.3.5 New Zealand
8.3.6 Rest of Asia Pacific
8.4 Rest of the World
8.4.1 Middle East
8.4.2 Brazil
8.4.3 Argentina
8.4.4 South Africa
8.4.5 Egypt

9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies

10 Company Profiling
10.1 GlaxoSmithKline
10.2 Eli Lilly and Company
10.3 F. Hoffmann-LA Roche Ltd
10.4 Amgen Inc.
10.5 Ablynx NV
10.6 Bristol-Myers Squibb
10.7 Janssen Global Services, LLC (Johnson and Johnson)
10.8 Astrazeneca
10.9 Biovest International Inc
10.10 Bayer AG
10.11 Oxford BioTherapeutics Ltd.
10.12 Pfizer
10.13 Genentech Inc
10.14 Merck
10.15 Bellicum Pharmaceuticals Inc
10.16 Novartis

List of Tables
Table 1 Global Cancer Immunotherapy Market Outlook, By Region (2013-2022) ($MN)
Table 2 Global Cancer Immunotherapy Market Outlook, By Application (2013-2022) ($MN)
Table 3 Global Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2013-2022) ($MN)
Table 4 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 5 Global Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2013-2022) ($MN)
Table 6 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 7 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 8 Global Cancer Immunotherapy Market Outlook, By Melanoma (2013-2022) ($MN)
Table 9 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 10 Global Cancer Immunotherapy Market Outlook, By Other Cancer Types (2013-2022) ($MN)
Table 11 Global Cancer Immunotherapy Market Outlook, By Product Type (2013-2022) ($MN)
Table 12 Global Cancer Immunotherapy Market Outlook, By Vaccines (2013-2022) ($MN)
Table 13 Global Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
Table 14 Global Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2013-2022) ($MN)
Table 15 Global Cancer Immunotherapy Market Outlook, By Immunomodulators (2013-2022) ($MN)
Table 16 Global Cancer Immunotherapy Market Outlook, By Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF) (2013-2022) ($MN)
Table 17 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2013-2022) ($MN)
Table 18 Global Cancer Immunotherapy Market Outlook, By Immunity as an Ally (2013-2022) ($MN)
Table 19 Global Cancer Immunotherapy Market Outlook, By Immunotherapy (2013-2022) ($MN)
Table 20 Global Cancer Immunotherapy Market Outlook, By Approved Products & Clinical Trails (2013-2022) ($MN)
Table 21 Global Cancer Immunotherapy Market Outlook, By Immunity as an Obstacle (2013-2022) ($MN)
Table 22 Global Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2013-2022) ($MN)
Table 23 Global Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2013-2022) ($MN)
Table 24 Global Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 25 Global Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2013-2022) ($MN)
Table 26 Global Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2013-2022) ($MN)
Table 27 Global Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2013-2022) ($MN)
Table 28 Global Cancer Immunotherapy Market Outlook, By Cell Therapies (2013-2022) ($MN)
Table 29 Global Cancer Immunotherapy Market Outlook, By Dendritic Cells (2013-2022) ($MN)
Table 30 Global Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2013-2022) ($MN)
Table 31 Global Cancer Immunotherapy Market Outlook, By Check Point Inhibitors (2013-2022) ($MN)
Table 32 Global Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2013-2022) ($MN)
Table 33 Global Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2013-2022) ($MN)
Table 34 Global Cancer Immunotherapy Market Outlook, By End User (2013-2022) ($MN)
Table 35 Global Cancer Immunotherapy Market Outlook, By Clinics (2013-2022) ($MN)
Table 36 Global Cancer Immunotherapy Market Outlook, By Hospital (2013-2022) ($MN)
Table 37 Global Cancer Immunotherapy Market Outlook, By Other End Users (2013-2022) ($MN)
Table 38 North America Cancer Immunotherapy Market Outlook, By Country (2013-2022) ($MN)
Table 39 North America Cancer Immunotherapy Market Outlook, By Application (2013-2022) ($MN)
Table 40 North America Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2013-2022) ($MN)
Table 41 North America Cancer Immunotherapy Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 42 North America Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2013-2022) ($MN)
Table 43 North America Cancer Immunotherapy Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 44 North America Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 45 North America Cancer Immunotherapy Market Outlook, By Melanoma (2013-2022) ($MN)
Table 46 North America Cancer Immunotherapy Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 47 North America Cancer Immunotherapy Market Outlook, By Other Cancer Types (2013-2022) ($MN)
Table 48 North America Cancer Immunotherapy Market Outlook, By Product Type (2013-2022) ($MN)
Table 49 North America Cancer Immunotherapy Market Outlook, By Vaccines (2013-2022) ($MN)
Table 50 North America Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
Table 51 North America Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2013-2022) ($MN)
Table 52 North America Cancer Immunotherapy Market Outlook, By Immunomodulators (2013-2022) ($MN)
Table 53 North America Cancer Immunotherapy Market Outlook, By Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF) (2013-2022) ($MN)
Table 54 North America Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2013-2022) ($MN)
Table 55 North America Cancer Immunotherapy Market Outlook, By Immunity as an Ally (2013-2022) ($MN)
Table 56 North America Cancer Immunotherapy Market Outlook, By Immunotherapy (2013-2022) ($MN)
Table 57 North America Cancer Immunotherapy Market Outlook, By Approved Products & Clinical Trails (2013-2022) ($MN)
Table 58 North America Cancer Immunotherapy Market Outlook, By Immunity as an Obstacle (2013-2022) ($MN)
Table 59 North America Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2013-2022) ($MN)
Table 60 North America Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2013-2022) ($MN)
Table 61 North America Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 62 North America Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2013-2022) ($MN)
Table 63 North America Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2013-2022) ($MN)
Table 64 North America Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2013-2022) ($MN)
Table 65 North America Cancer Immunotherapy Market Outlook, By Cell Therapies (2013-2022) ($MN)
Table 66 North America Cancer Immunotherapy Market Outlook, By Dendritic Cells (2013-2022) ($MN)
Table 67 North America Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2013-2022) ($MN)
Table 68 North America Cancer Immunotherapy Market Outlook, By Check Point Inhibitors (2013-2022) ($MN)
Table 69 North America Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2013-2022) ($MN)
Table 70 North America Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2013-2022) ($MN)
Table 71 North America Cancer Immunotherapy Market Outlook, By End User (2013-2022) ($MN)
Table 72 North America Cancer Immunotherapy Market Outlook, By Clinics (2013-2022) ($MN)
Table 73 North America Cancer Immunotherapy Market Outlook, By Hospital (2013-2022) ($MN)
Table 74 North America Cancer Immunotherapy Market Outlook, By Other End Users (2013-2022) ($MN)
Table 75 Europe Cancer Immunotherapy Market Outlook, By Country (2013-2022) ($MN)
Table 76 Europe Cancer Immunotherapy Market Outlook, By Application (2013-2022) ($MN)
Table 77 Europe Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2013-2022) ($MN)
Table 78 Europe Cancer Immunotherapy Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 79 Europe Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2013-2022) ($MN)
Table 80 Europe Cancer Immunotherapy Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 81 Europe Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 82 Europe Cancer Immunotherapy Market Outlook, By Melanoma (2013-2022) ($MN)
Table 83 Europe Cancer Immunotherapy Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 84 Europe Cancer Immunotherapy Market Outlook, By Other Cancer Types (2013-2022) ($MN)
Table 85 Europe Cancer Immunotherapy Market Outlook, By Product Type (2013-2022) ($MN)
Table 86 Europe Cancer Immunotherapy Market Outlook, By Vaccines (2013-2022) ($MN)
Table 87 Europe Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
Table 88 Europe Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2013-2022) ($MN)
Table 89 Europe Cancer Immunotherapy Market Outlook, By Immunomodulators (2013-2022) ($MN)
Table 90 Europe Cancer Immunotherapy Market Outlook, By Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF) (2013-2022) ($MN)
Table 91 Europe Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2013-2022) ($MN)
Table 92 Europe Cancer Immunotherapy Market Outlook, By Immunity as an Ally (2013-2022) ($MN)
Table 93 Europe Cancer Immunotherapy Market Outlook, By Immunotherapy (2013-2022) ($MN)
Table 94 Europe Cancer Immunotherapy Market Outlook, By Approved Products & Clinical Trails (2013-2022) ($MN)
Table 95 Europe Cancer Immunotherapy Market Outlook, By Immunity as an Obstacle (2013-2022) ($MN)
Table 96 Europe Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2013-2022) ($MN)
Table 97 Europe Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2013-2022) ($MN)
Table 98 Europe Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 99 Europe Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2013-2022) ($MN)
Table 100 Europe Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2013-2022) ($MN)
Table 101 Europe Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2013-2022) ($MN)
Table 102 Europe Cancer Immunotherapy Market Outlook, By Cell Therapies (2013-2022) ($MN)
Table 103 Europe Cancer Immunotherapy Market Outlook, By Dendritic Cells (2013-2022) ($MN)
Table 104 Europe Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2013-2022) ($MN)
Table 105 Europe Cancer Immunotherapy Market Outlook, By Check Point Inhibitors (2013-2022) ($MN)
Table 106 Europe Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2013-2022) ($MN)
Table 107 Europe Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2013-2022) ($MN)
Table 108 Europe Cancer Immunotherapy Market Outlook, By End User (2013-2022) ($MN)
Table 109 Europe Cancer Immunotherapy Market Outlook, By Clinics (2013-2022) ($MN)
Table 110 Europe Cancer Immunotherapy Market Outlook, By Hospital (2013-2022) ($MN)
Table 111 Europe Cancer Immunotherapy Market Outlook, By Other End Users (2013-2022) ($MN)
Table 112 Asia Pacific Cancer Immunotherapy Market Outlook, By Country (2013-2022) ($MN)
Table 113 Asia Pacific Cancer Immunotherapy Market Outlook, By Application (2013-2022) ($MN)
Table 114 Asia Pacific Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2013-2022) ($MN)
Table 115 Asia Pacific Cancer Immunotherapy Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 116 Asia Pacific Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2013-2022) ($MN)
Table 117 Asia Pacific Cancer Immunotherapy Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 118 Asia Pacific Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 119 Asia Pacific Cancer Immunotherapy Market Outlook, By Melanoma (2013-2022) ($MN)
Table 120 Asia Pacific Cancer Immunotherapy Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 121 Asia Pacific Cancer Immunotherapy Market Outlook, By Other Cancer Types (2013-2022) ($MN)
Table 122 Asia Pacific Cancer Immunotherapy Market Outlook, By Product Type (2013-2022) ($MN)
Table 123 Asia Pacific Cancer Immunotherapy Market Outlook, By Vaccines (2013-2022) ($MN)
Table 124 Asia Pacific Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
Table 125 Asia Pacific Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2013-2022) ($MN)
Table 126 Asia Pacific Cancer Immunotherapy Market Outlook, By Immunomodulators (2013-2022) ($MN)
Table 127 Asia Pacific Cancer Immunotherapy Market Outlook, By Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF) (2013-2022) ($MN)
Table 128 Asia Pacific Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2013-2022) ($MN)
Table 129 Asia Pacific Cancer Immunotherapy Market Outlook, By Immunity as an Ally (2013-2022) ($MN)
Table 130 Asia Pacific Cancer Immunotherapy Market Outlook, By Immunotherapy (2013-2022) ($MN)
Table 131 Asia Pacific Cancer Immunotherapy Market Outlook, By Approved Products & Clinical Trails (2013-2022) ($MN)
Table 132 Asia Pacific Cancer Immunotherapy Market Outlook, By Immunity as an Obstacle (2013-2022) ($MN)
Table 133 Asia Pacific Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2013-2022) ($MN)
Table 134 Asia Pacific Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2013-2022) ($MN)
Table 135 Asia Pacific Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 136 Asia Pacific Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2013-2022) ($MN)
Table 137 Asia Pacific Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2013-2022) ($MN)
Table 138 Asia Pacific Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2013-2022) ($MN)
Table 139 Asia Pacific Cancer Immunotherapy Market Outlook, By Cell Therapies (2013-2022) ($MN)
Table 140 Asia Pacific Cancer Immunotherapy Market Outlook, By Dendritic Cells (2013-2022) ($MN)
Table 141 Asia Pacific Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2013-2022) ($MN)
Table 142 Asia Pacific Cancer Immunotherapy Market Outlook, By Check Point Inhibitors (2013-2022) ($MN)
Table 143 Asia Pacific Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2013-2022) ($MN)
Table 144 Asia Pacific Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2013-2022) ($MN)
Table 145 Asia Pacific Cancer Immunotherapy Market Outlook, By End User (2013-2022) ($MN)
Table 146 Asia Pacific Cancer Immunotherapy Market Outlook, By Clinics (2013-2022) ($MN)
Table 147 Asia Pacific Cancer Immunotherapy Market Outlook, By Hospital (2013-2022) ($MN)
Table 148 Asia Pacific Cancer Immunotherapy Market Outlook, By Other End Users (2013-2022) ($MN)
Table 149 RoW Cancer Immunotherapy Market Outlook, By Country (2013-2022) ($MN)
Table 150 RoW Cancer Immunotherapy Market Outlook, By Application (2013-2022) ($MN)
Table 151 RoW Cancer Immunotherapy Market Outlook, By Multiple Myeloma (2013-2022) ($MN)
Table 152 RoW Cancer Immunotherapy Market Outlook, By Prostate Cancer (2013-2022) ($MN)
Table 153 RoW Cancer Immunotherapy Market Outlook, By Head & Neck Cancer (2013-2022) ($MN)
Table 154 RoW Cancer Immunotherapy Market Outlook, By Lung Cancer (2013-2022) ($MN)
Table 155 RoW Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2013-2022) ($MN)
Table 156 RoW Cancer Immunotherapy Market Outlook, By Melanoma (2013-2022) ($MN)
Table 157 RoW Cancer Immunotherapy Market Outlook, By Breast Cancer (2013-2022) ($MN)
Table 158 RoW Cancer Immunotherapy Market Outlook, By Other Cancer Types (2013-2022) ($MN)
Table 159 RoW Cancer Immunotherapy Market Outlook, By Product Type (2013-2022) ($MN)
Table 160 RoW Cancer Immunotherapy Market Outlook, By Vaccines (2013-2022) ($MN)
Table 161 RoW Cancer Immunotherapy Market Outlook, By Therapeutic Vaccines (2013-2022) ($MN)
Table 162 RoW Cancer Immunotherapy Market Outlook, By Prophylactic Vaccines (2013-2022) ($MN)
Table 163 RoW Cancer Immunotherapy Market Outlook, By Immunomodulators (2013-2022) ($MN)
Table 164 RoW Cancer Immunotherapy Market Outlook, By Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF & G-CSF) (2013-2022) ($MN)
Table 165 RoW Cancer Immunotherapy Market Outlook, By Oncolytic Virus (2013-2022) ($MN)
Table 166 RoW Cancer Immunotherapy Market Outlook, By Immunity as an Ally (2013-2022) ($MN)
Table 167 RoW Cancer Immunotherapy Market Outlook, By Immunotherapy (2013-2022) ($MN)
Table 168 RoW Cancer Immunotherapy Market Outlook, By Approved Products & Clinical Trails (2013-2022) ($MN)
Table 169 RoW Cancer Immunotherapy Market Outlook, By Immunity as an Obstacle (2013-2022) ($MN)
Table 170 RoW Cancer Immunotherapy Market Outlook, By Interferons (IFN) (2013-2022) ($MN)
Table 171 RoW Cancer Immunotherapy Market Outlook, By Interleukins (IL) (2013-2022) ($MN)
Table 172 RoW Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2013-2022) ($MN)
Table 173 RoW Cancer Immunotherapy Market Outlook, By Bispecific Monoclonal Antibodies (2013-2022) ($MN)
Table 174 RoW Cancer Immunotherapy Market Outlook, By Naked Monoclonal Antibodies (2013-2022) ($MN)
Table 175 RoW Cancer Immunotherapy Market Outlook, By Conjugated Monoclonal Antibodies (2013-2022) ($MN)
Table 176 RoW Cancer Immunotherapy Market Outlook, By Cell Therapies (2013-2022) ($MN)
Table 177 RoW Cancer Immunotherapy Market Outlook, By Dendritic Cells (2013-2022) ($MN)
Table 178 RoW Cancer Immunotherapy Market Outlook, By Chimeric Antigen Receptor (CAR) T Cell Therapy (2013-2022) ($MN)
Table 179 RoW Cancer Immunotherapy Market Outlook, By Check Point Inhibitors (2013-2022) ($MN)
Table 180 RoW Cancer Immunotherapy Market Outlook, By Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) (2013-2022) ($MN)
Table 181 RoW Cancer Immunotherapy Market Outlook, By Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4) (2013-2022) ($MN)
Table 182 RoW Cancer Immunotherapy Market Outlook, By End User (2013-2022) ($MN)
Table 183 RoW Cancer Immunotherapy Market Outlook, By Clinics (2013-2022) ($MN)
Table 184 RoW Cancer Immunotherapy Market Outlook, By Hospital (2013-2022) ($MN)
Table 185 RoW Cancer Immunotherapy Market Outlook, By Other End Users (2013-2022) ($MN)



【レポートのキーワード】

癌免疫療法、ワクチン、免疫調節物質、モノクローナル抗体、細胞治療、チェックポイント阻害剤

★調査レポート[癌免疫療法の世界市場見通し:ワクチン、免疫調節物質、モノクローナル抗体、細胞治療、チェックポイント阻害剤] (コード:SMRC611044)販売に関する免責事項を必ずご確認ください。
★調査レポート[癌免疫療法の世界市場見通し:ワクチン、免疫調節物質、モノクローナル抗体、細胞治療、チェックポイント阻害剤]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆